$56,704,950
to MAPP BIOPHARMACEUTICAL, INC.
IGF::OT::IGF
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Support biopharmaceutical development and manufacturing capabilities through the Office of Assistant Secretary for Preparedness and Response.
ASPR awards fund medical countermeasures and pandemic preparedness infrastructure critical to U.S. public health emergency response.
Investment in domestic biopharmaceutical manufacturing capacity strengthens supply chain resilience for critical medical products.
Domestic biotech manufacturing reduces reliance on foreign supply chains for vaccines and therapeutics during health emergencies.
Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002179.
- 2026-05-12PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES$184.8M
- 2026-02-20THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.$110.9M
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50118C00024_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.